^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
GynTect®

Company:
Oncgnostics
Type:
Other Approval
Evidence

News

1m
GynTect® Methylation Markers detect recurrent disease in patients treated for CIN3 with high sensitivity and specificity in a retrospective case-control study (DKK 2024)
For initially GynTect-positive patients both hrHPV and GynTect® assays detect recurrent disease with similar sensitivity but the GynTect® assay has a significantly higher specificity. A future study will have to show whether cytology/GynTect® co-testing will out-perform cytology/hrHPV co-testing in post-treatment surveillance for this subgroup of CIN3 patients.
Retrospective data
|
GynTect®
5ms
Molecular biological cancer diagnostics close gaps in cancer screening (Oncgnostics Press Release)
"oncgnostics GmbH will present its molecular biological cancer diagnostics, its products and current study results at MEDICA, the largest trade fair in the medical industry. Oncgnostics develops patented, highly informative biomarkers. This technology improves existing cervical cancer diagnostics and also, using liquid biopsy, lays the foundation for early detection of head and neck tumours."
Clinical data
|
GynTect®
7ms
Hong Kong firm invests in jena-based Oncgnostics GmbH (Oncgnostics Press Release)
"The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer diagnostic Gyntect for the reliable detection of cervical cancer...Following the successful launch of Oncgnostics’ test in China, Grande Bio-tech Co. Ltd. has decided to make a financial commitment. The goal now is to expand the distribution of tests developed by Oncgnostics in the ASEAN countries."
Financing • Commercial
|
GynTect®
8ms
Evaluation of CIN2/3 Lesion Regression in GynTect DNA Methylation-Marker-Negative Patients in a Longitudinal Study. (PubMed, Cancers (Basel))
Thus, the clinical relevance for an implementation of the GynTect assay for patients undergoing watchful waiting remains questionable. Further studies with longer observation periods should be undertaken.
Journal • Observational data • Epigenetic controller
|
GynTect®
1year
Promoter hypermethylation analysis of host genes in cervical intraepithelial neoplasia and cervical cancers on histological cervical specimens. (PubMed, BMC Cancer)
The promoter methylation of six tumor suppressor genes is related to the severity of cervical lesions. The GynTect® assay based on cervical specimens provides diagnostic values for detecting CIN2 + and CIN3 + .
Journal
|
SOX17 (SRY-Box Transcription Factor 17) • ITGA4 (Integrin, alpha 4) • DLX1 (Distal-Less Homeobox 1)
|
GynTect®
over1year
In-depth methylation analysis of the epigenetic marker regions ASTN1, DLX1, ITGA4, RXFP3, SOX17 and ZNF671 in cervical precancerous lesions and cervical carcinoma (DKK 2022)
Methylation of the six marker regions is at least a conse- quence of, if not even the cause for cervical carcinogenesis.
SOX17 (SRY-Box Transcription Factor 17) • ITGA4 (Integrin, alpha 4) • DLX1 (Distal-Less Homeobox 1)
|
GynTect®
over1year
German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China (Oncgnostics Press Release)
"The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. The product is the first approved methylation test for triage of HPV-positive cases in China...The molecular biological test GynTect developed by oncgnostics clarifies early on whether a patient with an abnormal finding after undergoing cervical cancer screening has a predisposition for or already has cervical carcinoma (cervical cancer), resulting in the need for prompt treatment."
Non-US regulatory
|
GynTect®